Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders

Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders

A new approach is adopted to treat primary immunodeficiency disorders, such as the severe combined immunodeficiency (SCID; e.g., adenosine deaminase SCID [ADA-SCID] and IL-2 receptor X-linked severe combined immunodeficiency [SCID-X1]). The success, along with the feasibility of gene therapy, is und...

Full description

Bibliographic Details
Main Authors: Odiba Arome Solomon, Okoro Nkwachukwu Oziamara, Durojaye Olanrewaju Ayodeji, Wu Yanjun
Format: Article
Language:English
Published: De Gruyter 2021-05-01
Series:Open Life Sciences
Subjects:
clinical trials
gene therapy
hemoglobin
hemophilia b
neurodegenerative
ocular
Online Access:https://doi.org/10.1515/biol-2021-0033

Internet

https://doi.org/10.1515/biol-2021-0033

Similar Items